Free Trial

Bausch + Lomb (BLCO) Stock Forecast & Price Target

Bausch + Lomb logo
$18.00 +0.05 (+0.28%)
(As of 12/20/2024 05:31 PM ET)

Bausch + Lomb - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
7
Buy
5

Based on 13 Wall Street analysts who have issued ratings for Bausch + Lomb in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 1 has given a sell rating, 7 have given a hold rating, and 5 have given a buy rating for BLCO.

Consensus Price Target

$20.58
14.35% Upside
According to the 13 analysts' twelve-month price targets for Bausch + Lomb, the average price target is $20.58. The highest price target for BLCO is $26.00, while the lowest price target for BLCO is $17.00. The average price target represents a forecasted upside of 14.35% from the current price of $18.00.
Get the Latest News and Ratings for BLCO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bausch + Lomb and its competitors.

Sign Up

BLCO Analyst Ratings Over Time

TypeCurrent Forecast
12/24/23 to 12/23/24
1 Month Ago
11/24/23 to 11/23/24
3 Months Ago
9/25/23 to 9/24/24
1 Year Ago
12/24/22 to 12/24/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
Hold
7 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$20.58$20.91$19.14$19.55
Forecasted Upside14.35% Upside6.84% Upside-0.38% Downside23.71% Upside
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy

BLCO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BLCO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bausch + Lomb Stock vs. The Competition

TypeBausch + LombMedical CompaniesS&P 500
Consensus Rating Score
2.31
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside14.35% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent BLCO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/12/2024Bank of America
3 of 5 stars
 Reiterated RatingUnderperform$18.00-2.49%
12/12/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00+26.65%
12/11/2024Citigroup
3 of 5 stars
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$24.00 ➝ $22.00+6.43%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$19.00-4.14%
10/31/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$23.00 ➝ $26.00+28.21%
10/31/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
10/22/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$20.00 ➝ $23.00+14.71%
10/15/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
V. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$19.00 ➝ $25.00+19.90%
9/23/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$16.00 ➝ $19.00-4.81%
8/1/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$14.00 ➝ $18.00+4.05%
8/1/2024Evercore
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetIn-Line$15.50 ➝ $17.00-1.85%
7/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Nachman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$19.00+23.94%
2/26/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$17.00 ➝ $18.00+2.27%
8/3/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$22.00 ➝ $25.00+34.48%
2/23/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$15.00 ➝ $17.00-6.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:55 AM ET.


BLCO Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Bausch + Lomb is $20.58, with a high forecast of $26.00 and a low forecast of $17.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last year. There is currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLCO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCO, but not buy additional shares or sell existing shares.

According to analysts, Bausch + Lomb's stock has a predicted upside of 14.35% based on their 12-month stock forecasts.

Over the previous 90 days, Bausch + Lomb's stock had 2 downgrades and 1 upgrade by analysts.

Bausch + Lomb has been rated by research analysts at Bank of America, Citigroup, Evercore ISI, HC Wainwright, Morgan Stanley, Needham & Company LLC, Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.

Analysts like Bausch + Lomb less than other "medical" companies. The consensus rating for Bausch + Lomb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BLCO compares to other companies.


This page (NYSE:BLCO) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners